An Open Study to Investigate the Safety and Efficacy of Optivate® in Severe Haemophilia A Patients.

Human Cell Line-derived Recombinant Factor VIII (Human-cl-rhFVIII) in Previously Untreated Patients

NCT01712438 ·Status: COMPLETED ·Phase: PHASE3

A Study to Compare the Pharmacokinetics and Safety of Optivate® and Haemate P® in Patients With Von Willebrand Disease.

NCT02250508 ·Status: COMPLETED ·Phase: PHASE2

An Open Study to Investigate the Safety and Efficacy of Replenine®-VF in Severe Haemophilia B Patients

NCT02231944 ·Status: COMPLETED ·Phase: PHASE3

Optivate in People With Von Willebrand Disease Undergoing Surgery

NCT00404300 ·Status: TERMINATED ·Phase: PHASE3

Efficacy and Safety Study of Human-cl rhFVIII in PTPs With Severe Hemophilia A

NCT01125813 ·Status: COMPLETED ·Phase: PHASE3

Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia A

NCT00989196 ·Status: COMPLETED ·Phase: PHASE2

A Study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Patients Undergoing Major Surgery.

NCT02250560 ·Status: COMPLETED ·Phase: PHASE3

Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery

NCT01561391 ·Status: COMPLETED ·Phase: PHASE4

A Study With OPTIVATE® in People With Von Willebrand Disease

NCT00387192 ·Status: TERMINATED ·Phase: PHASE3

Comparison of Efficacy, Safety and Costs of Recombinant FVIII Products Between On-demand and Secondary Prophylaxis Groups in Haemophilia A Patients

NCT01817868 ·Status: COMPLETED

Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A

NCT01454739 ·Status: COMPLETED ·Phase: PHASE3

Trial of Rituximab Versus Oral Cyclophosphamide to Eradicate or Suppress Autoimmune Anti-Factor VIII Antibodies in Acquired Hemophilia A

NCT00306670 ·Status: TERMINATED ·Phase: PHASE2/PHASE3

Validation Study of a cOmputer Pharmacokinetic Tool to assIst in the Follow up Care of haeMophilia A Patients

NCT01436825 ·Status: COMPLETED

Retrospective Chart Review to Evaluate Safety and Tolerability of ADVATE Among Previously Untreated Patients in China With Moderate to Severe Hemophilia A

NCT02634723 ·Status: COMPLETED

A Study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Patients Under the Age of 6 Years

NCT02263469 ·Status: COMPLETED ·Phase: PHASE3

Assess the Efficacy and Safety of Personalized Prophylaxis Human-cl rhFVIII in Patients With Severe Haemophilia A

NCT02256917 ·Status: COMPLETED ·Phase: PHASE3

An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A

NCT01486927 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Clinical and Health-related Outcome of rFVIIIFc Prophylaxis

NCT04583930 ·Status: UNKNOWN

An Open-study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Subjects Undergoing Surgery

NCT02250573 ·Status: COMPLETED ·Phase: PHASE3

Safety, Tolerability, and Efficacy Study of Valoctocogene Roxaparvovec in Hemophilia A With Active or Prior Inhibitors

NCT04684940 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2

Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Congenital Hemophilia A

NCT01434511 ·Status: TERMINATED ·Phase: PHASE3

Study of Next-Generation Recombinant Factor IX Variant in Adult Subjects With Hemophilia B

NCT03995784 ·Status: COMPLETED ·Phase: PHASE2

Extension at 10 Years of the: "Observational Study Evaluating Efficacy and Costs of Secondary Prophylaxis vs On-demand Therapy With Kogenate Bayer in Patients With Severe Haemophilia A."

NCT02581969 ·Status: COMPLETED

Post Marketing Surveillance To Observe Safety And Efficacy Of Xyntha® In Subjects With Hemophilia A

NCT01790828 ·Status: COMPLETED

ADVATE 2 mL Post-Authorization Safety Surveillance (PASS)

NCT02093741 ·Status: COMPLETED